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ABSTRACT
Human immunodeficiency virus type 1 (HIV-1)
transcriptional transactivator (Tat) recruits the
positive transcription elongation factor b (P-TEFb)
to the viral promoter. Consisting of cyclin depen-
dent kinase 9 (Cdk9) and cyclin T1, P-TEFb
phosphorylates RNA polymerase II and the negative
transcription elongation factor to stimulate the
elongation of HIV-1 genes. A major fraction of
nuclear P-TEFb is sequestered into a transcription-
ally inactive 7SK small nuclear ribonucleoprotein
(snRNP) by the coordinated actions of the 7SK
small nuclear RNA (snRNA) and hexamethylene
bisacetamide (HMBA) induced protein 1 (HEXIM1).
In this study, we demonstrate that Tat prevents the
formation of and also releases P-TEFb from the 7SK
snRNP in vitro and in vivo. This ability of
Tat depends on the integrity of its N-terminal
activation domain and stems from the high affinity
interaction between Tat and cyclin T1, which allows
Tat to directly displace HEXIM1 from cyclin T1.
Furthermore, we find that in contrast to the
Tat-independent activation of the HIV-1 promoter,
Tat-dependent HIV-1 transcription is largely insen-
sitive to the inhibition by HEXIM1. Finally, primary
blood lymphocytes display a reduced amount of the
endogenous 7SK snRNP upon HIV-1 infection. All
these data are consistent with the model that Tat
not only recruits but also increases the active pool
of P-TEFb for efficient HIV-1 transcription.
INTRODUCTION
Transcription of the HIV-1 proviral DNA by RNA
polymerase II (RNAPII) is controlled primarily at the
level of elongation by the viral Tat protein (1). In its
absence, RNAPII clears the HIV-1 promoter but soon
arrests due to actions of the negative transcription
elongation factor (N-TEF), yielding predominantly short
viral transcripts that contain the transactivation response
element (TAR) elements at their 50 ends. To stimulate
elongation, Tat binds to TAR via its arginine-rich motif
(ARM). Moreover, the activation domain of Tat,
consisting of the N-terminal core and cysteine-rich
regions, binds cyclin T1 (CycT1), which interacts with
Cdk9 to form the positive transcription elongation factor
b (P-TEFb) (2). The highly cooperative interactions
between Tat, TAR and P-TEFb recruit P–TEFb to the
paused transcription complex, where it phosphorylates
the C-terminal domain (CTD) of the largest subunit of
RNAPII and the components of N-TEF (negative
transcription elongation factor). These events convert
N–TEF into a positive elongation factor and recruit pre-
mRNA splicing and 30 polyadenylation machineries to the
phosphorylated CTD, resulting in eﬃcient elongation and
co-transcriptional processing of nascent pre-mRNA (1).
Recent reports indicate that P–TEFb exist in two
mutually exclusive complexes that diﬀer in their kinase
activities. In HeLa cells, about half of P–TEFb are
sequestered in a catalytically inactive complex together
with the 7SK snRNA (7SK) and the HEXIM1 protein
(3,4). Whereas HEXIM1 binds P–TEFb by interacting
directly with CycT1 via its C–terminal region, 7SK serves
as a molecular scaﬀold to facilitate the HEXIM1-P-TEFb
binding (5–9). Besides the 7SK-HEXIM1–P-TEFb com-
plex (referred herein as 7SK snRNP), another complex in
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Brd4–P-TEFb complex (10,11). The Brd4-bound P–TEFb
is transcriptionally active and recruited to transcriptional
templates possibly due to the ability of Brd4, a bromo-
domain protein, to bind acetylated histones and the
mediator. Importantly, the partitioning of P-TEFb into
the inactive and active complexes is dynamic, and
several stress-inducing agents are known to disrupt
the 7SK snRNP and stimulate the formation of the
Brd4–P-TEFb complex (11). Finally, recent ﬁndings
obtained in heart, breast epithelial, neuroblastoma
and murine erythroleukemia cells suggest that a shift in
the equilibrium between the two P–TEFb fractions may
alter the cellular developmental commitments, leading
to either unrestrained growth or terminal diﬀerentiation
(12–15).
Since most of the P-TEFb are sequestered in the
catalytically inactive and active complexes in cells, Tat
could in principle modulate their conﬁgurations to
increase the pool of P-TEFb for eﬃcient HIV-1 transcrip-
tion. Notably, Tat recruits P-TEFb to the HIV-1 LTR
independently of Brd4 (11). However, it is unclear whether
Tat aﬀects the inactive 7SK snRNP. In this study, the
apparent similarities in the molecular RNA:protein
conﬁgurations between the HIV-1 TAR-Tat-P-TEFb
and the inactive 7SK snRNP prompted us to investigate
whether Tat releases P-TEFb from the 7SK snRNP.
Indeed, we ﬁnd that Tat disrupts 7SK snRNP in cells and
releases P-TEFb from it via its activation domain. This
disruption could be attributed to a direct competition
between Tat and HEXIM1 for binding to CycT1. Thus, it
appears that HIV-1 has evolved an eﬃcient mechanism
that alleviates the negative regulation of P-TEFb by
hijacking it from the inactive 7SK snRNP to activate
HIV-1 transcription.
MATERIALS AND METHODS
Cellculture
The HeLa-based HL3T1 cell line that contains an
integrated HIV LTR-luciferase was a gift of Dr Romero
(San Francisco State University). The HeLa-based F1C2
cells stably expressing Cdk9-F were described (11). The
cells were grown at 378C with 5% CO2 in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 10% fetal
calf serum, 100mM L–glutamine and 50mg each of
penicilin and streptomycin per ml.
Plasmid DNAs
Plasmids coding for GST-T1, Tat and CycT1-binding
domain of HEXIM1 (HEXIM1-TBD) were described (7).
Plasmid reporter pSLIIBCAT and a plasmid coding for
the Rev-CycT1 chimera were described (16). Plasmids
coding for Tat-F, Tat-HA, the various mutant Tat
proteins and F-HEXIM1 were described (3,6).
Recombinant proteins, RNA and immunological reagents
The anti–CycT1 and anti-Cdk9 antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
The anti–FLAG M2 antibody and the anti–FLAG M2
beads were purchased from Sigma–Aldrich Corp (St.
Louis, MO, USA). Recombinant CycT1, Tat and
HEXIM1 proteins, either alone or as GST-chimeras
were expressed and puriﬁed from E. coli as described
(7). A 29–mer HIV-1 TAR RNA was transcribed in vitro
from an antisense single-stranded oligonucleotide using
the T7 promotor and polymerase system.
GST-pull downassays
For direct competition assays between HEXIM1-TBD,
GST-T1 and Tat,  2mg GST or GST-fusion proteins were
immobilized on glutathione Sepharose-beads (Amersham)
and incubated with 5mg of HEXIM1-TBD and increasing
amounts of Tat (1–20mg) and TAR. Bindings were
performed in 300ml of 20mM Tris/HCl (pH 7.4),
100mM NaCl, 20mM ZnSO4, 0.5% NP-40, 5mM
b-mercaptoethanol buﬀer solution at room temperature
(RT) for 0.5–1h. Beads were washed 2–3 times in the same
buﬀer and bound proteins were analyzed by SDS-PAGE
and Coomassie staining.
Fluorescence spectroscopymeasurements and data analysis
Conditions for the protein binding and replacement assays
as well as the subsequent ﬂuorescence measurements have
been described previously (7). Binding curves, titration
and dissociation experiments were analyzed with
Origin 7.0 (OriginLab Corporation, MA, USA). Kinetic
dissociation measurements were done using a SX.18MV
stopped ﬂow apparatus (Applied Photophysics) by rapidly
mixing of a pre-equilibrated solution of 5mM CycT1 and
5mM dimeric HEXIM1-TBD
  with 10 or 20mM excess
of Tat or Tat/TAR, respectively. The dansyl-based
ﬂuorophore was excited at 337nm, and the ﬂuorescence
emission was recorded through a 420nm cutoﬀ ﬁlter. The
competition measurements were evaluated with the soft-
ware Scientist v2.01 (MicroMath Scientiﬁc Software,
UT, USA).
Affinity purification of FLAG and HA epitope-tagged
proteins and their associated factors
For western and northern analyses, FLAG- or HA-tagged
HEXIM proteins were expressed in HeLa cells transfected
with the Lipofectamine Plus reagent (Invitrogen). Nuclear
extracts (NEs) were prepared from the transfected
cells 48h later and immunopuriﬁcations were done as
described (17). Northern blotting employed the full-length
7SK antisense RNA as a probe as described previously (6).
The 7SK snRNP in vitro reconstitution assay was
performed as described (18).
Transient transfection andCAT reporter geneassay
HeLa cells were seeded into 6-well plates or 100-mm-
diameter petri dishes  12h prior to transfection and
transfected with FuGENE6 reagent (Roche Applied
Science, Indianapolis, IN, USA). CAT enzymatic assays
were performed as described (16).
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Eight hours post-transfection, HL3T1 cells were treated or
untreated with PMA (100ng/ml). After an additional 24h,
cells were washed twice with PBS and lysed by three
freeze–thaw cycles. Luciferase activity was measured in a
microplate reader (LB96V MicroLumat Plus) using 50ml
of each sample. To normalize the results, protein
concentrations were measured using Bradford reagent
(Biorad).
Glycerol gradientsedimentation analysis
NEs, prepared from HeLa cells either untransfected or
transfected with the WT Tat–F–expressing vector at 48h
post-transfection, were subjected to ultracentrifugation in
a Sorvall SW41 Ti rotor at 38000 r.p.m. for 21h at 48C
in a 10ml glycerol gradient solution (10–30%) containing
20mM HEPES, pH 7.9, 0.3M KCl, 0.2mM EDTA and
0.1% NP40. Fractions were collected and analyzed as
described (17).
Infection of primary cells
Primary blood lymphocytes (PBLs; 5 10
7 cells) from
healthy donors were stimulated with PHA (3mg/ml) and
IL-2 (100U/ml) for 3 days prior to infection with two
diﬀerent amounts of the HIV-1 Lai strain (0.5 and 5ng
of p24). The cells were exposed to the virus for 3h in 2%
FCS medium and were maintained in the RPMI medium
containing 10% FCS, supplemented with PHA and IL-2.
Five days later, the eﬃciency of infection was veriﬁed by
measuring the amounts of p24 in the supernatants, and the
cells were harvested for glycerol gradient sedimentation
analysis.
RESULTS
Tat displaces HEXIM1 fromthe native 7SKsnRNP invitro
Previous studies demonstrated that HEXIM1 and Tat
interact with CycT1 in a region that is immediately
C-terminal to the cyclin box (4,7,19), suggesting that the
interactions of Tat and HEXIM1 with CycT1 may be
mutually exclusive. To test this possibility, we performed
a binding assay with recombinant proteins to study the
competition between Tat and the CycT1–binding domain
of HEXIM1 (HEXIM1-TBD; aa 255–359) (7) for binding
to the chimeric GST-CycT1 (GST-T1; aa 1–292). Data in
Figure 1A indicate that HEXIM1-TBD bound to GST–T1
but not GST alone in the absence of Tat (compare lanes
1 and 2). However, the addition of increasing amounts of
HIV-1 Tat protein and TAR RNA (kept at an 1:1 molar
ratio) displaced HEXIM1-TBD from GST-T1 in a
dose-dependent manner (lanes 3–8). Notably, the absence
of TAR slightly decreased the ability of Tat to compete
with HEXIM1-TBD for binding to CycT1 in vitro (data
not shown). This issue will be addressed in more detail
in Figure 2.
The above experiments used recombinant HEXIM1 and
CycT1 protein fragments. To extend these ﬁndings,
we asked whether Tat could displace HEXIM1 from
CycT1 in the context of the native 7SK snRNP in vitro.
First, to examine the eﬀect of Tat on the formation of the
7SK snRNP in HeLa nuclear extracts (NE), we employed
a previously described in vitro reconstitution assay (18).
In this system, the HeLa-based F1C2 cell line expressing
the FLAG–tagged Cdk9 protein (Cdk9-F) was used to
immobilize P-TEFb on anti-FLAG beads. Whereas high
Figure 1. Tat disrupts the HEXIM1-P-TEFb interaction in vitro.
(A) Competition between HEXIM1-TBD and Tat for binding to
GST-T1. GST alone (lane 1) or GST-T1 (lanes 2–8) was incubated with
HEXIM1-TBD. Increasing amounts of Tat and TAR (kept at an 1:1
molar ratio) were added to the reactions in lanes 3–8. The bound
proteins were detected in a Coomassie–stained SDS-gel. Lanes 9 and 10
represent 40% of the input proteins. The bands denoted with a star
(
 ) represent degradation products of GST-T1. (B) Tat suppresses
the in vitro reconstitution of 7SK snRNP. To the immobilized P-TEFb
(through Cdk9-F), RNase A-treated or untreated HeLa NE (lanes
1 and 2) or NE containing the wild-type or mutant Tat-HA proteins
(lanes 3 and 4) was added as indicated. The amounts of 7SK and
HEXIM1 bound to P-TEFb (left panel) and the levels of Tat-HA
proteins in NE (right panel) are determined by northern and western
blotting. (C) Tat disrupts the 7SK snRNP in vitro. 7SK snRNP
immobilized on anti-Cdk9 beads were incubated with the wild-type
or mutant C22G GST-Tat chimeras as indicated. The levels of
Cdk9-bound HEXIM1 (left panel) and the input GST-Tat chimeras
(right panel) are determined by western blotting.
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P-TEFb, the 7SK snRNP could be reconstituted with the
addition of HeLa NE.
Indeed, NE prepared from untransfected HeLa cells
reconstituted the interactions of HEXIM1 and 7SK
with P-TEFb and the presence of RNase A prevented
these interactions (Figure 1B, compare lanes 1 and 2).
Importantly, the addition of NE prepared from HeLa cells
expressing the transfected, HA-tagged wild-type
Tat protein (Tat-HA) reduced the bindings of HEXIM1
and 7SK to P-TEFb. In contrast, the incubation with NE
containing the mutant Tat protein (C22G), which does not
bind CycT1 due to a point mutation in its activation
domain (19), failed to reduce these bindings (Figure 1B,
compare lanes 3 and 4). Thus, Tat was able to compete
with the full-length HEXIM1 for binding to CycT1 even
in the context of the native 7SK snRNP.
Next, we asked whether Tat could disrupt a preformed
7SK snRNP, which was immunopuriﬁed from HeLa NE
with antibodies directed against the endogenous Cdk9.
While the addition of the wild-type GST-Tat chimera
completely disrupted the HEXIM1-P-TEFb interaction,
the mutant GST-Tat C22G had a signiﬁcantly reduced
eﬀect (Figure 1C, lanes 2 and 3). The residual activity
displayed by this mutant could be due to its weak, but still
detectable binding to P-TEFb (data not shown). Taken
together, these results suggest that Tat not only decreases
the formation of but also disrupts a preformed 7SK
snRNP in vitro. Moreover, this ability of Tat likely stems
from its direct displacement of HEXIM1 from CycT1.
Tat displaces HEXIM1 from CycT1 invitro due toits
higher affinity forCycT1
To directly compare the CycT1-binding abilities of
HEXIM1 and Tat, we performed a series of ﬂuorescence
emission assays, which detect protein complex formation
based on the general principle that a solvent exposed
B
N
HEXIM1
-TBD*
I.
GST-T1
Zn Zn
HIV-1
Tat
II.
II.
400 450 500 550 600
0
0.2
0.4
0.6
0.8
1.0
1.2
Wavelength (nm)
R
e
l
a
t
i
v
e
 
f
l
u
o
r
e
s
c
e
n
c
e
 
(
A
U
)
 
HEXIM1
-TBD*
I. add GST-T1
II.add Tat
I. II.
01234
1.00
1.05
1.10
1.15
1.20
R
e
l
a
t
i
v
e
 
f
l
u
o
r
e
s
c
e
n
c
e
 
(
A
U
)
Concentration Tat (mM)
Dissociation of HEXIM1-TBD*
from GST-T1 by addition of Tat
0.70
0.75
0.80
0.85
0.90
0.95
1.00
1.05
0.0 0.5 1.0 1.5 2.0
Buffer
2 × TBD
2 × Tat
2 × Tat/TAR
4 × Tat
4 × Tat/TAR
Time (s)
R
e
l
a
t
i
v
e
 
f
l
u
o
r
e
s
c
e
n
c
e
 
(
A
U
)
D
A
C
Figure 2. Tat displaces HEXIM1-TBD from CycT1 due to its higher aﬃnity for CycT1. (A) A schematic diagram of the main steps of the
ﬂuorescence competition assay. GST-T1 was ﬁrst added to HEXIM1-TBD
  (step I), followed by the addition of Tat (step II). (B) Fluorescence
emission spectra of the two-step titrations as diagrammed in A. To 1.0mM HEXIM1-TBD
  (black curve), 1.0mM of GST-T1 was added (red),
followed by an excess of 5.0mM Tat (green). (C) Dissociation of the HEXIM1-TBD
  from GST-T1 by increasing concentrations of Tat.
The displacement of HEXIM1-TBD
  from GST-T1 by Tat was observed by equilibrium ﬂuorescence titration. To a preformed complex of 2.0mM
HEXIM-TBD
  and 1.0mM GST-T1, Tat was added at concentrations from 0.2–4mM. (D) Kinetics of the Tat- or Tat/TAR-mediated displacement of
HEXIM1-TBD
  from GST-T1 as measured by stopped ﬂow techniques. To a pre-equilibrated solution of 5mM GST-T1 and 5mM dimeric HEXIM1-
TBD
 , Tat or Tat/TAR was injected at a concentration of 10 (2 )o r2 0 mM( 4  ) to displace HEXIM1-TBD
  over the indicated time periods
(in seconds). The displacement caused by buﬀer alone or 10mM( 2  ) unlabeled HEXIM1-TBD (labeled as TBD) is also presented as a comparison.
2006 Nucleic Acids Research, 2007, Vol. 35, No. 6ﬂuorescence label emits a signal of lower intensity than a
label in a tight molecular environment. Following a two-
step titration strategy outlined in Figure 2A, an equal
concentration of GST-T1 was added to a solution contain-
ing 1mM of ﬂuorescently labeled HEXIM1-TBD
(HEXIM1-TBD
 ). This was followed by the addition
of 5mM of recombinant Tat protein to the reaction
mixture. The equilibrium titration of this
reaction scheme was monitored by ﬂuorescence emission
spectroscopy (Figure 2B). Starting from the spectra of
unbound HEXIM1-TBD
  (black line), we ﬁrst observed an
increase in ﬂuorescence emission upon the HEXIM1-
TBD
 –GST-T1 complex formation (red line). However,
upon the addition of Tat, the spectra returned to the
groundstate(greenline),implicatingareleaseofHEXIM1-
TBD
  by the binding of Tat to GST-T1.
Next, we followed the dissociation of HEXIM1-TBD
 
from GST-T1 by the addition of Tat in a ﬂuorescence
competition experiment involving 2.0mM of HEXIM1-
TBD
  and 1.0mM GST-T1 proteins (Figure 2C).
Increasing concentrations of Tat from 0.2 to 4mM led to
a decrease in the ﬂuorescence signal, indicating the ability
of Tat to displace HEXIM1-TBD  from GST–T1. A ﬁt of
the steady-state curve yielded an  10-fold higher aﬃnity
of GST–T1 for Tat than for HEXIM1-TBD
 .
Finally, to analyze the impact of the HIV-1 TAR RNA
on the ability Tat to displace HEXIM1-TBD
  from
GST-T1 in a quantitative manner, we performed fast
stopped ﬂow kinetic measurements (Figure 2D). To a pre-
equilibrated solution containing 5mM GST-T1 and 5mM
dimeric HEXIM1–TBD
 , Tat was injected at a concentra-
tion of 10 (2 )o r2 0mM( 4  ). Compared to buﬀer alone,
a dose-dependent decrease in the ﬂuorescence signal and
thus release of HEXIM–TBD
  from GST-T1 was
observed. Addition of equal concentrations of TAR to
Tat further enhanced this displacement (Figure 2D). From
a ﬁt of the competition displacement curves, we deter-
mined the kinetic parameters of the GST-T1–Tat interac-
tion. The presence of TAR apparently increased the kon
rate by a factor of 1.5–2 and decreased koﬀ by a factor of
2–3. Overall, the aﬃnity of Tat/TAR to GST-T1
compared to Tat alone was increased by a factor of 5,
leading to an increased displacement of HEXIM1-TBD
 
from GST-T1. Taken together, these results suggest that
Tat displays a higher aﬃnity for CycT1 than does
HEXIM1 and is thus able to directly displace HEXIM1
from CycT1. Moreover, the presence of TAR enhances
the ability of recombinant Tat to disrupt the
HEXIM1–CycT1 interaction possibly due to stabilization
of the Tat conformation and/or its solubility.
Tat preventsthe binding ofHEXIM1 toP-TEFb invivo
The in vitro observations presented so far prompted us to
examine whether Tat could block the binding of HEXIM1
to P-TEFb in vivo. To test this hypothesis, we examined
the abilities of wild-type and mutant Tat proteins to
compete with co-expressed HEXIM1 for binding to the
endogenous P-TEFb in HeLa cells. As indicated above,
this ability of Tat is expected to depend on the integrity of
the Tat N-terminal activation domain that is involved in
the Tat–CycT1 interaction. Additionally, the arginine-rich
motif (ARM) of Tat, which is critical for TAR RNA
binding and nuclear localization, could contribute to this
eﬀect as well.
First, we examined the abilities of the various FLAG-
tagged Tat proteins (Tat-F) to interact with the Cdk9
subunit of the endogenous P-TEFb (Figure 3A). Western
blotting of anti–FLAG immunoprecipitates revealed that
wild-type Tat-F interacted with Cdk9 in the absence of
the HIV-1 TAR RNA (lane 1). Similarly, a mutant
Tat (Tat-NLS
SV40), whose ARM was replaced with the
nuclear localization signal (NLS) derived from the SV40 T
antigen, also bound Cdk9 (lane 2), further implicating a
TAR-independent interaction between Tat and P–TEFb.
As expected, the C22G mutation within the Tat activation
domain in either the wild–type or mutant Tat-NLS
SV40
background abolished this interaction (Figure 3A,
lanes 3 and 4).
Consistent with their abilities to interact with P-TEFb,
both wild-type Tat and Tat–NLS
SV40 eﬃciently prevented
the interaction of the co-expressed F-HEXIM1 protein
with endogenous P-TEFb (Figure 3B, lanes 2 and 4).
In contrast, neither Tat C22G nor C22G–NLS
SV40 was
able to disrupt the interaction between F-HEXIM1 and
P-TEFb (lanes 3 and 5). These observations indicate that
the ability of Tat to prevent the formation of the 7SK
snRNP depended on the interaction of Tat with P-TEFb
but not the TAR RNA. Thus, these in vivo results diﬀered
from the in vitro ﬂuorescence competition data described
above (Figure 2D), which revealed a TAR RNA-mediated
enhancement of the displacement of HEXIM1-TBD from
GST-T1 by Tat. As discussed below, this discrepancy
could result from an improved, TAR-dependent folding
and structural integrity of bacterially produced recombi-
nant Tat proteins.
To demonstrate the direct competition between Tat and
HEXIM1 for binding to P-TEFb in vivo, we performed a
titration experiment in which levels of F-HEXIM1
were kept constant while amounts of the co-expressed
Tat-F were increased in 2-fold increments (Figure 3C).
The interactions of these two FLAG-tagged proteins with
the endogenous P–TEFb were determined by anti-Cdk9
immunoprecipitation followed by western blotting.
Indeed, Tat prevented HEXIM1 from interacting with
P-TEFb in a dose-dependent manner (Figure 3C, right
panel). Taken together, these in vivo data corroborate well
with the above in vitro analyses by showing that Tat
disrupted the binding between HEXIM1 and P-TEFb via
its N-terminal P–TEFb–binding domain.
Tatdisrupts the endogenous 7SKsnRNP invivo
To further our in vivo ﬁndings, we next investigated
whether Tat could also disrupt the pre-existing 7SK
snRNP in HeLa cells. Indeed, the expression of the
wild-type Tat and mutant Tat-NLS
SV40 proteins, both of
which bound P-TEFb, eﬃciently disrupted the endoge-
nous 7SK snRNP, as evidenced by the marked reduction
in the amounts of 7SK and HEXIM1 associated with the
immunoprecipitated Cdk9 (Figure 4A, lanes 3 and 5). In
contrast, the C22G and C22G–NLS
SV40 mutants, which
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of 7SK snRNP (Figure 4A, lanes 4 and 6).
The notion of a Tat-mediated disruption of pre-existing
7SK snRNPs was further addressed by the glycerol
gradient sedimentation analysis of the distributions of
P-TEFb complexes in HeLa cells that expressed Tat
or not. In NE that did not contain Tat, about half of
P-TEFb and 20–30% of total cellular HEXIM1 were
sequestered in the 7SK snRNP (Figure 4B, lanes 6–8).
The other half of P-TEFb, which bound to Brd4 in a salt-
sensitive manner (11), were converted into the smaller,
free P-TEFb form under our sedimentation conditions
(lanes 3–5). In contrast, this HEXIM1 and P-TEFb
distribution pattern was changed considerably in NE
that contained Tat. Levels of HEXIM1 in the 7SK snRNP
were diminished greatly and this eﬀect was accom-
panied by a simultaneous reduction in the amounts of
both CycT1 and Cdk9 in the same fractions (fractions 6–8)
and by the accumulation of free HEXIM1 proteins
(fractions 2 and 3). Thus, these observations are consis-
tent with the co-immunoprecipitation data shown above
and suggest strongly that Tat not only prevents the
formation of new but also disrupts pre-existing 7SK
snRNP in cells.
Tat suppresses HEXIM1’s inhibition of
P-TEFb-dependent transcription
Thus far, our data obtained in vitro and in vivo illustrate
the ability of Tat to disrupt the interaction between
P-TEFb and HEXIM1. Based on this Tat-mediated
release of an inhibitor from P-TEFb, one could envision
that Tat might be able to antagonize the inhibitory
action of HEXIM1 on P-TEFb-dependent transcription.
To test this hypothesis, we performed transcriptional
assays in HeLa cells, in which the ability of P-TEFb
to stimulate transcription was monitored by using an
RNA-tethering system consisting of the plasmid reporter
pSLIIBCAT and the hybrid Rev-CycT1 protein. The
recruitment of CycT1 and its associated Cdk9 protein to
pSLIIBCAT via the Rev–RRE interaction activates
transcription that depends on the kinase activity of
P-TEFb (16).
When Rev-CycT1 was co-expressed with pSLIIBCAT
in HeLa cells, levels of CAT activity increased  6-fold
over the basal level (Figure 5, compare bars 1 and 2).
As expected, the co-expression of F-HEXIM1 decreased
the Rev-CycT1-dependent transcription to  2-fold
(Figure 5, bar 3). Importantly, the expression of wild-
type Tat-F largely reversed the inhibitory eﬀect of
F-HEXIM1, whereas the mutant Tat C22G protein
failed to do so (bars 4 and 5). It is important to point
out that this Tat-mediated increase in transcription was
indeed due to the ability of Tat to neutralize HEXIM1’s
negative eﬀect, as the expression of Tat alone in the
absence of Rev-CycT1 and HEXIM1 only minimally
increased transcription over the basal level (compare bars
1, 4 and 6). Thus, the release of HEXIM1 from P-TEFb
by Tat has a clear functional consequence and allows Tat
to antagonize the HEXIM1-mediated inhibition of
P–TEFb’s transcriptional activity.
Cdk9
Tat-F
C22G
WT
NLS SV40
C22G-NLS SV40
Tat-F&
mutants:
A
1234
7SK
F-HEXIM1
CycT1
Cdk9
Tat-HA
& mutants
12345
WT
C22G
C22G-NLS SV40
NLS SV40
Tat-HA:
aFlag IP
NE
F-HEXIM1: +++++
F-HEXIM1
B
C
12 3 123
F-HEXIM1
Tat-F
Cdk9
NE aCdk9 IP
NE
aFlag IP
Tat-F (mg):
F-HEXIM1 (mg): 22 22 22
2 24 48 8
Cdk9
CycT1
7SK
Cdk9
Tat-F
Figure 3. Tat prevents HEXIM1 from binding to P-TEFb in vivo.
(A) Western analyses of the levels of Cdk9 as well as the indicated wild-
type or mutant Tat-F proteins in NEs of transfected HeLa cells (upper
panels; all plasmids transfected at 2mg per 15-cm dish) and the levels of
Cdk9 associated with Tat-F in the anti-FLAG immunoprecipitates
(lower panels). (B) HeLa cells were co-transfected with appropriate
empty vectors ( ) or vectors coding for F-HEXIM1 (2mg/15-cm dish)
and various Tat-HA proteins (2mg) as indicated (total 4mg plasmid
DNA per dish). The levels of F-HEXIM1, Tat-HA, 7SK, CycT1 and
Cdk9 in NEs (top ﬁve panels) and the amounts of 7SK, CycT1 and
Cdk9 bound to the immunoprecipitated F-HEXIM1 (bottom four
panels) are examined by western and northern blotting. (C) HeLa cells
were co-transfected with a constant amount (2mg/15-cm dish) of the
plasmid coding for F-HEXIM1 and increasing amounts (2, 4 and 8mg)
of the plasmid coding for wild-type Tat-F. The levels of F-HEXIM1,
Tat-F and Cdk9 proteins in NEs of transfected cells as well as the
amounts of F-HEXIM1 and Tat-F proteins bound to the immunopre-
cipitated Cdk9 are detected by western blotting and shown in the left
and right panels, respectively.
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to theinhibition byHEXIM1
Our demonstration that Tat antagonizes HEXIM1 by
disrupting the 7SK snRNP raises an intriguing possibility
that Tat transactivation of the HIV-1 LTR would be
largely refractory to HEXIM1’s inhibitory action. To test
this hypothesis, we examined eﬀects of HEXIM1 on Tat
transactivation of the integrated HIV-1 LTR that controls
the expression of the luciferase reporter gene in the
HeLa-based HL3T1 cells. As expected, the expression
of Tat-F stimulated the HIV-1 transcription potently
(Figure 6A, compare bars 1 and 2). However, the
expression of increasing amounts of F-HEXIM1 did not
cause a signiﬁcant decrease in Tat-dependent HIV–1
transcription (bars 3–5), suggesting that HEXIM1 failed
to inhibit Tat transactivation.
Since transcriptional activation of the HIV-1 LTR
could also be achieved in a Tat–independent manner
by inducing the transcriptional activity of NF-kB with
PMA (20), we next tested whether HEXIM1 could
aﬀect the PMA-stimulated HIV-1 transcription. In con-
trast to Tat-dependent activation, the robust stimulation
of the integrated HIV-1 LTR by PMA was decreased
progressively by F–HEXIM1 in a dose-dependent manner
(Figure 6B, bars 1–4). This ﬁnding is consistent with a
previous report showing that HEXIM1 expression
reduced the transcription from an NF-kB-dependent
reporter plasmid (21). Of note, PMA treatment of cells
B
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wild-type or mutant Tat-F proteins were subjected to anti-Cdk9 or, as a
negative control, anti-Cdk4 immunoprecipitation. The levels of
endogenous 7SK, CycT1 and HEXIM1 bound to Cdk9 as revealed
by northern or western blotting are indicated (bottom panels).
The upper panels show the levels of the endogenous 7SK, CycT1,
HEXIM1 and Cdk9 as well as the various transfected Tat-F proteins in
HeLa NEs. (B) NEs prepared from HeLa cells transfected with an
empty vector ( ) or the Tat-F-encoding plasmid (20mg/15-cm dish)
were subjected to glycerol gradient sedimentation analysis. The panels
show the western detection of CycT1, HEXIM1 and Cdk9 in gradient
fractions (left). Molecular size standards were analyzed in a parallel
gradient and their positions indicated by arrows.
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Figure 5. Tat reverses the HEXIM1-mediated inhibition of P-TEFb
transcriptional activity. HeLa cells were co-transfected with the reporter
plasmid pSLIIBCAT (0.2mg) and the plasmids coding for the various
eﬀectors (Rev-CycT1: 0.6mg; F-HEXIM1: 0.6mg; Tat-F: 0.8mg;
TatC22G-F: 0.8mg) as indicated. The chloramphenicol acetyltransferase
(CAT) enzyme activities in cell lysates were measured and the error
bars represent the mean þ/  SD. Lower panel shows the expression
levels of the co-transfected F-HEXIM1 and Tat-F as revealed by
western blotting.
Nucleic Acids Research, 2007, Vol. 35, No. 6 2009failed to disrupt the endogenous 7SK snRNP (data not
shown). Thus, the Tat-dependent and -independent
activation of HIV-1 transcription displayed distinct
sensitivities to HEXIM1 inhibition. It is likely that the
Tat-mediated disruption of the HEXIM1-P-TEFb inter-
action was responsible for the inability of HEXIM1 to
inhibit Tat transactivation.
HIV-1 infection ofprimary bloodlymphocytes results in
areduced amountof theendogenous 7SK snRNP
Since Tat prevents the formation of and also releases
P-TEFb from the 7SK snRNP, we were prompted to
investigate whether the amount of endogenous 7SK
snRNP was also aﬀected in HIV-1-infected cells.
To address this question, we infected the primary blood
lymphocytes (PBLs) with the HIV-1 Lai strain at two
diﬀerent concentrations that yielded 3.22ng/ml (1 ) and
6.32ng/ml (2 ) of HIV p24 in the supernatant after ﬁve
days of infection. The distributions of P-TEFb
complexes between infected and uninfected cells were
then compared by the glycerol gradient sedimentation
analysis (Figure 7). In total cell lysates of PBLs that were
not exposed to HIV-1,  80% of total cellular Cdk9,
CycT1 and HEXIM1 were present in the large 7SK
snRNP (Figure 7, lanes 7 and 8). However, these
distribution patterns were changed in cell lysates of
infected PBLs. We observed that with increasing virus
concentration and thereby more Tat expression, there was
a dosage-dependent reduction in the levels of HEXIM1,
Cdk9 and CycT1 in the 7SK snRNP (fractions 7 and 8).
Meanwhile, the levels of Cdk9 and CycT1 in the smaller
size, 7SK/HEXIM1-free P-TEFb (fractions 3–5) as well as
the amounts of released HEXIM1 (fractions 2–4) also
showed a concomitant increase. Although it is unclear at
present whether these changes could be entirely attributed
to the action of Tat, the dosage-dependent reduction in
7SK snRNP in HIV-1-infected PBLs are nevertheless
consistent with our extensive in vitro and in vivo ﬁndings
presented above and suggest that Tat could disrupt the
7SK snRNP when expressed in the course of HIV-1
infection.
DISCUSSION
Tat has long been recognized as a critical HIV-1
regulatory protein that recruits the cellular co-factor
P-TEFb to the viral LTR to stimulate transcription
elongation. In this report, we present evidence that Tat
not only recruits but also increases the active pool of
P-TEFb for HIV-1 transcription. Our in vitro, in vivo and
functional studies indicate that Tat accomplishes this task
by competing with HEXIM1 for binding to CycT1.
Compared to HEXIM1, Tat binds to the same region of
CycT1 but with higher aﬃnity, allowing it to displace
HEXIM1 from P–TEFb. As a result, Tat prevents the
formation of new 7SK snRNPs as well as disrupts
pre–existing ones. Thus, approximately half of the total
P–TEFb that would otherwise be sequestered and inactive
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2010 Nucleic Acids Research, 2007, Vol. 35, No. 6in the 7SK snRNP, are now available for Tat
transactivation.
Our in vitro and in vivo data conﬁrmed and extended
a recent report showing that Tat and the HEXIM1-TBD
bound to CycT1 in vitro in a mutually exclusive
manner (7). Despite the fact that the HIV-1 TAR RNA
is involved in cooperative interactions with both Tat and
P-TEFb in vitro (19,22), it did not play any signiﬁcant role
in the Tat displacement of HEXIM1 from P-TEFb in vivo
(Figures 3 and 4). Likewise, ectopic expression of HIV-1
TAR RNA did not further enhance this displacement
(data not shown). Rather, the N-terminal activation/
P-TEFb-binding domain of Tat was critical for this eﬀect.
However, our in vitro ﬂuorescence competition experi-
ments containing recombinant proteins and protein
fragments suggest that the presence of the HIV-1 TAR
RNA enhanced the ability of Tat to displace
HEXIM1-TBD from CycT1 (Figure 2D). The apparent
discrepancy between our in vivo and in vitro analyses may
be explained by the fact that bacterially expressed Tat
proteins are often folded improperly and the presence of
HIV-1 TAR RNA may act as a molecular chaperone to
induce a higher order structure of Tat in vitro. In contrast,
Tat proteins expressed in human cells are likely to be
modiﬁed correctly and display improved structural
integrity, which may be responsible for our observed
TAR-independent displacement of HEXIM1 from
P-TEFb in vivo.
In contrast to our results, a recent report suggested that
overexpression of HEXIM1 results in a decreased
Tat transactivation (23). However, the seemingly discre-
pancy between these two studies could stem from the
diﬀerent experimental conditions. For example, Fraldi
et al. (23) used a much higher HEXIM1 versus Tat
plasmid ratio in their experiments, which may have caused
a relatively small amount of Tat to be overwhelmed by a
large excess of HEXIM1. As a result, the shift of the
P-TEFb equilibrium from the Tat-bound toward the
HEXIM1–bound state may have led to the observed
inhibition of Tat-transactivation by HEXIM1. Notably,
even under such conditions, HEXIM1 displayed only a
modest, 2-fold inhibitory eﬀect (23). In addition, the fact
that their study employed an episomal HIV-1-LTR
promoter but not an integrated one as in our experiments
could have also contributed to the diﬀerent observations.
Importantly, the analyses of the endogenous 7SK
snRNP in HIV-1-infected primary cells have furthered
our extensive in vitro and in vivo competition studies and
revealed the physiological signiﬁcance of our ﬁndings.
We demonstrate that an eﬃcient and dosage–dependent
disruption of the inactive 7SK snRNP occurred in the
HIV-1-infected PBLs. Although indirect eﬀects of HIV-1
infection cannot be completely ruled out at this stage, our
ﬁndings are nevertheless consistent with the notion that
the local Tat recruitment of P-TEFb from 7SK snRNP
can take place, especially since abundant P-TEFb
complexes are found on the HIV-1 LTR in the presence
of Tat (1).
Because very few free P-TEFb exist in the cell and most
of them are sequestered in two main complexes (10,11),
it is not too surprising that Tat has to disrupt the 7SK
snRNP for eﬃcient HIV transcription. Besides this
inactive P-TEFb complex, it has been suggested that the
disruption of the active Brd4–P-TEFb complex by Tat
also favors HIV-1 transactivation (11). Since the bindings
of Brd4 and Tat to P-TEFb are mutually exclusive, the
Brd4–P-TEFb interaction that normally recruits P–TEFb
to chromatin templates for general elongation has to be
disrupted by Tat for activated HIV transcription (11).
These ﬁndings, together with the Tat–mediated disruption
of the 7SK snRNP presented here, reveal a clear
preference of Tat to bind and recruit the free form of
P–TEFb to the HIV-1 LTR.
Our demonstration that Tat releases P-TEFb from 7SK
snRNP reveals important insights into how this transcrip-
tional kinase contributes to Tat function. Despite the fact
that it originates from the inactive pool, this P-TEFb is
nevertheless expected to be fully active. This is because
P–TEFb within the 7SK snRNP is phosphorylated on
threonine 186at the tip of the Cdk9T-loop (18,24). As a
hallmark of any activated Cdks, this event is expected to
render the catalytic pocket in Cdk9 in an open conforma-
tion. Thus, the Tat-bound P-TEFb is pre-activated and
ready to phosphorylate its substrates once liberated from
7SK snRNP.
Based on the data presented in this study, we propose
a simple ‘coupling’ model for Tat transactivation of HIV
transcription. This model suggests that the inactive 7SK
snRNP and active Tat-bound P-TEFb reside in close
proximity within the cell nucleus and are exchanging
rapidly during viral replication. Indeed, HEXIM1 and
P-TEFb have been found in or near nuclear speckles
(8,25,26). Notably, Tat redirects CycT1 out of this
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of HIV-1 p24 detected in the supernatants at day 5 post infection.
Nucleic Acids Research, 2007, Vol. 35, No. 6 2011sub-nuclear compartment (26), which could reﬂect the
release of P-TEFb from 7SK snRNP. Thus, a role for Tat
in the dynamic and rapid deployment of P-TEFb to sites
of active viral replication is envisioned. In this scenario,
Tat not only recruits P-TEFb to the initiating RNAPII via
TAR, but also ensures an ample supply of the kinase for
the rapid replication and spread of HIV in the infected
host. Future studies are necessary to investigate the
importance of this newly discovered Tat function to HIV
infection, replication and the escape from viral latency.
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